Common name: Sorafenib; BAY 43-9006; Nexavar; Sorafenib tosylate
Trademarks: Nexavar
Molecular Formula: C21H16ClF3N4O3
CAS Registry Number: 284461-73-0; 475207-59-1 (tosylate)
CAS Name: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
Molecular Weight: 464.825
Activity: Oncolytic Drugs; Protein Kinase Inhibitor; Primary Kidney Cancer; Advanced Renal Cell Carcinoma; Advanced Primary Liver Cancer; Hepatocellular Carcinoma; Radioactive Iodine Resistant Advanced Thyroid Carcinoma; Multikinase Inhibitor; RAF Inhibitor; VEGFR-1,2,3 Inhibitior; PDGFR Inhibitor
Sorafenib synthesis: WO2000042012A1
References:
1. Dumas, J.; et. al. omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors. WO2000042012A1
2. Dumas, J.; et. al. omega-Carboxyaryl Substituted Diphenyl Ureas as RAF kinase inhibitors. US7235576
3. Lögers, M.; et. al. Process for the preparation of 4 – {4 – [( {[4-chloro-3-(TRIFLUOROMETHYL) phenyl] amino} carbonyl) amino] phenoxy}-N-methylpyridine-2-carboxamide. WO2006034796
4. Bankston, D.; et. al. A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer. Org Proc Res Dev 2002, 6 (6), 777-781.
